Circulating tumor DNA analysis to guide adjuvant therapy in stage II colon cancer
Dr. Jeanne Tie
The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) predicts poor recurrence-free survival, whereas its absence predicts low risk of recurrence. The multinational DYNAMIC study found that a ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival.
